Evidence map›Paper›PMID 38881546›Full record

SynthesisFrontiers in psychiatry2024

Deep transcranial magnetic stimulation for schizophrenia: a systematic review.

Yu Mo, Zhan-Ming Shi, Xin-Hu Yang, Xian-Jun Lan, Can-Jin Deng, Xing-Bing Huang, Xiao-Lin Tan, Saxby Pridmore, Gabor S Ungvari, Yu-Tao Xiang and 1 more

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yu Mo *Department of Psychiatry, The Brain Hospital of Guangxi Zhuang Autonomous Region, LiuZhou, China.
Zhan-Ming Shi *Department of Psychiatry, Chongqing Jiangbei Second Hospital, Chongqing, China.
Xin-Hu Yang *Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
Xian-Jun LanDepartment of Psychiatry, The Brain Hospital of Guangxi Zhuang Autonomous Region, LiuZhou, China.
Can-Jin DengDepartment of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
Xing-Bing HuangDepartment of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
Xiao-Lin TanDepartment of Psychiatry, Chongqing mental health center, Chongqing, China.
Saxby PridmoreDiscipline of Psychiatry, University of Tasmania, Hobart, TAS, Australia.
Gabor S UngvariSection of Psychiatry, University of Notre Dame Australia, Fremantle, WA, Australia.
Yu-Tao XiangUnit of Psychiatry, Department of Public Health and Medicinal Administration, & Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macao, Macao SAR, China.
Wei ZhengDepartment of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The efficacy and safety of deep transcranial magnetic stimulation (dTMS) as an intervention for schizophrenia remain unclear. This systematic review examined the efficacy and safety of dTMS for schizophrenia. Methods: A systematic search of Chinese (WanFang and Chinese Journal Net) and English databases (PubMed, EMBASE, PsycINFO, and Cochrane Library) were conducted. Results: Three randomized clinical trials (RCTs) comprising 80 patients were included in the analyses. Active dTMS was comparable to the sham treatment in improving total psychopathology, positive symptoms, negative symptoms, and auditory hallucinations measured by the Positive and Negative Syndrome Scale (PANSS), the Scale for the Assessment of Positive Symptoms (SAPS), the Scale for the Assessment of Negative Symptoms (SANS), and the Auditory Hallucinations Rating Scale (AHRS), respectively. Only one RCT reported the effects on neurocognitive function measured by the Cambridge Neuropsychological Test Automated Battery (CANTAB), suggesting that dTMS may only improve one Stockings of Cambridge measure (i.e., subsequent times for five move problems). All three studies reported overall discontinuation rates, which ranged from 16.7% to 44.4%. Adverse events were reported in only one RCT, the most common being tingling/twitching (30.0%, 3/10), head/facial discomfort (30.0%, 3/10), and back pain (20.0%, 2/10). Conclusion: This systematic review suggests that dTMS does not reduce psychotic symptoms in schizophrenia, but it shows potential for improving executive functions. Future RCTs with larger sample sizes focusing on the effects of dTMS on psychotic symptoms and neurocognitive function in schizophrenia are warranted to further explore these findings.

Indexed as

deep transcranial magnetic stimulationexecutive functionpsychopathologyschizophreniasystematic review

Identifiers

PMID38881546
PMCPMC11176548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.